Business

August 7, 2014

Salix results fall short of expectations despite big jump in revenue

With an assist from its acquisition of specialty drug company Santarus, Salix Pharmaceuticals posted a 62 percent jump in revenue that nonetheless fell short of Wall Street's expectations.

Related content

Comments

Videos

Editor's Choice Videos